Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of topical CT327 ointment in mild to moderate atopic dermatitis with pruritus
2012-005389-36Phase 2Completed
- Sponsor
- Creabilis SA
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pegcantratinib in atopic dermatitis (AD) (3 arms), sponsored by Creabilis SA. Primary endpoints: Change from baseline in pruritus visual analogue scale and Controlled disease by Investigator Global Assessment. Started Mar 2013; status: completed.
02
Drugs
pegcantratinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2012-005389-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005389-36.